Denali Therapeutics, Inc. (DNLI)
20.00
-0.53
(-2.58%)
USD |
NASDAQ |
Oct 02, 16:00
20.02
+0.02
(+0.10%)
After-Hours: 20:00
Denali Therapeutics Net Income (Quarterly) : -127.55M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -127.55M |
| March 31, 2026 | -128.45M |
| December 31, 2025 | -128.55M |
| September 30, 2025 | -126.90M |
| June 30, 2025 | -124.12M |
| March 31, 2025 | -132.97M |
| December 31, 2024 | -114.75M |
| September 30, 2024 | -107.19M |
| June 30, 2024 | -99.03M |
| March 31, 2024 | -101.80M |
| December 31, 2023 | -119.47M |
| September 30, 2023 | -99.35M |
| June 30, 2023 | 183.38M |
| March 31, 2023 | -109.78M |
| December 31, 2022 | -98.68M |
| September 30, 2022 | -103.30M |
| June 30, 2022 | -58.79M |
| March 31, 2022 | -65.22M |
| December 31, 2021 | -75.26M |
| September 30, 2021 | -84.59M |
| Date | Value |
|---|---|
| June 30, 2021 | -60.69M |
| March 31, 2021 | -70.04M |
| December 31, 2020 | 244.88M |
| September 30, 2020 | -58.23M |
| June 30, 2020 | -58.76M |
| March 31, 2020 | -56.76M |
| December 31, 2019 | -54.02M |
| September 30, 2019 | -46.26M |
| June 30, 2019 | -58.34M |
| March 31, 2019 | -38.99M |
| December 31, 2018 | 77.53M |
| September 30, 2018 | -35.37M |
| June 30, 2018 | -54.72M |
| March 31, 2018 | -23.68M |
| December 31, 2017 | -22.89M |
| September 30, 2017 | -21.84M |
| June 30, 2017 | -22.13M |
| March 31, 2017 | -21.32M |
| December 31, 2016 | -19.35M |
| September 30, 2016 | -30.61M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.604M |
| Total Expenses (Quarterly) | 131.16M |
| EPS Diluted (Quarterly) | -0.681 |
| Enterprise Value | 2.522B |
| Gross Profit Margin (Quarterly) | -52.39% |
| Profit Margin (Quarterly) | -3.54K% |
| Earnings Yield | -14.19% |
| Normalized Earnings Yield | -14.19 |